10-K: Vivani Medical Prioritizes Obesity Portfolio, Reports Positive Preclinical Data

Vivani Medical shifts focus to obesity treatments, showcasing promising preclinical results for its NPM-115 implant.

Summary

• Vivani Medical, a preclinical-stage biopharmaceutical company, is developing miniaturized, subdermal implants for long-term drug delivery.
• The company's lead programs include NPM-115 for chronic weight management and NPM-119 for type 2 diabetes, both designed for six-month delivery.
• Vivani's NanoPortal technology uses a biocompatible titanium-oxide membrane with precisely sized nanotubes for controlled drug release.
• Preclinical data for NPM-115 showed approximately 20% weight loss in obese mice, comparable to semaglutide injections.
• NPM-139, a semaglutide implant, is in development for chronic weight management with potential for once-yearly administration.
• The company filed an IND for NPM-119, but the study is currently on clinical hold due to insufficient CMC information.
• Vivani plans to submit a Complete Response to the FDA in the first half of 2024 to lift the clinical hold.
• A securities purchase agreement was entered into for $15 million to fund operations.
• The company has 37 employees in its Biopharm Division and 7 in its Neuromodulation division as of December 31, 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive preclinical results and a strategic shift towards a high-potential market, the clinical hold on NPM-119 and the need for additional funding introduce significant risks and uncertainties.

Positives

• The NanoPortal technology has demonstrated near constant drug release in animal models for six months.
• Preclinical data for NPM-115 shows promising weight loss results comparable to semaglutide.
• NPM-139 has the potential for once-yearly administration, which could be a significant advantage.
• The company has a strategic focus on addressing medication non-adherence in chronic diseases.
• Vivani has established in-house research, development, and manufacturing capabilities.
• The company has a strong intellectual property portfolio with 14 issued U.S. patents and 12 patents in foreign jurisdictions.

Negatives

• The LIBERATE-1 study for NPM-119 is on full clinical hold due to insufficient CMC information.
• The company has incurred significant operating losses and negative operating cash flows since inception.
• Vivani is dependent on the successful development, regulatory approval, and commercialization of its product candidates.
• The company will require substantial additional financing to pursue its business objectives.
• Clinical development involves a lengthy and expensive process with uncertain outcomes.
• The company is subject to a multitude of manufacturing risks, including reliance on third parties.

Risks

• The company is a preclinical stage company with a limited operating history and no products approved for commercial sale.
• There is no assurance that the company will be able to obtain regulatory approval for its product candidates.
• The company may not be able to adequately protect its proprietary or licensed technology.
• The company may infringe the intellectual property rights of others.
• The company may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
• The company is subject to a multitude of manufacturing risks, including reliance on third parties.
• The company may experience delays in the commencement or completion of clinical trials.
• The company may experience difficulty identifying, training and/or certifying an adequate number of healthcare professionals to properly implant and, when appropriate, explant our drug implants candidates.
• The company may not be able to obtain and sustain an adequate level of reimbursement by third-party payors for our product candidates, if approved.

Future Outlook

Vivani plans to submit a Complete Response to the FDA in the first half of 2024 to lift the clinical hold on NPM-119 and file a new IND for NPM-115 by the end of 2024. The company also intends to advance feasibility assessments for NPM-139 in 2024.

Management Comments

• Vivanis main priority is the further development of the companys lead programs NPM-115 and NPM-119.
• Vivanis management team remained committed to identifying and exploring strategic options for the Neuromodulation Division.
• Moving forward, Vivanis focus will be on the further development of NPM-115, NPM-119, and its emerging pipeline of innovative miniature, long-term drug implants.

Industry Context

The document highlights the growing market for GLP-1 therapies in the treatment of type 2 diabetes and obesity, and the challenges associated with medication adherence and tolerability. Vivani aims to address these issues with its long-term implant technology.

Comparison to Industry Standards

• The document compares NPM-115's preclinical weight loss data to semaglutide (Ozempic/Wegovy), a leading GLP-1 agonist, indicating a competitive profile.
• The document references the FDA's concerns with Intarcia Therapeutics' ITCA 650 exenatide implant, highlighting the importance of controlled drug release, which Vivani aims to achieve with its NanoPortal technology.
• The document notes that current GLP-1 products have only 40-60% real-world medication adherence, indicating a significant unmet need that Vivani's long-term implants could address.
• The document mentions that Novo Nordisk's Wegovy (semaglutide injection) sold approximately nearly $4.5 billion in 2023, highlighting the large and growing market for GLP-1 therapy in the treatment of patients with obesity.

Management Changes

Legal Proceedings

• Three oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by Cortigent.
• Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately 5.1 million or about $5.6 million. The Company recorded a charge of $1,675,000 for the year ended December 31, 2022 related to this matter but plans to continue its appeal against the preliminary judgment.

Related Party Transactions

• Vivani and Cortigent entered into an Amendment No. 1 to the Transition Funding, Support and Services Agreement, where Vivani agreed to advance funds and provide services to Cortigent until the earlier of December 31, 2024 or the closing of an initial public offering of Cortigent.

Stakeholder Impact

• Shareholders face risks due to the company's preclinical stage, need for additional funding, and potential delays in clinical trials.
• Employees may be affected by potential changes in the company's strategy and operations.
• Patients may benefit from the development of new treatments for chronic diseases, but there is no guarantee of success.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• Submit a Complete Response to the FDA to lift the clinical hold on NPM-119.
• File a new IND to support a First-in-Human study with NPM-115.
• Initiate a First-in-Human study of NPM-115 and/or NPM-119 in the US or Australia.
• Advance the feasibility assessments for NPM-139 in 2024.
• Develop manufacturing capabilities and systems for future clinical development.

Key Dates

Keywords

drug implant, NanoPortal technology, GLP-1, exenatide, semaglutide, obesity, type 2 diabetes, chronic weight management, medication adherence, subdermal implant